Polyrizon Ltd. has entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S to supply clinical trial material for its PL-14 allergy blocker. The collaboration aims to support Polyrizon's planned 2025 clinical trial, which will evaluate the safety and efficacy of PL-14 as a novel allergy protection solution.
Polyrizon's PL-14 is an innovative intranasal hydrogel designed to form a thin shield containment barrier in the nasal cavity. This barrier intends to prevent allergens from contacting the nasal epithelial tissue, potentially functioning as a "biological mask." The company's proprietary Capture and Contain (C&C) hydrogel technology, comprised of naturally occurring building blocks, is delivered in the form of nasal sprays.
Tomer Izraeli, CEO of Polyrizon, stated, "We are pleased to have established this partnership with Eurofins CDMO Amatsiaquitaine S.A.S, which strengthens our preparation efforts for the upcoming PL-14 clinical trial. We believe that this collaboration marks a significant milestone in our journey toward providing effective allergy protection solutions to patients."
The manufacturing site is equipped to support the clinical trial material needs for the 2025 trial, adhering to high-quality and compliant development programs in line with USA and European regulatory standards. Eurofins CDMO, a prominent Contract Development & Manufacturing Organization, offers comprehensive solutions for preclinical and clinical outsourcing services, specializing in both drug substance/API and drug product development for biologics and small molecules.
Polyrizon is also developing its Trap and Target (T&T) technology, focused on nasal delivery of active pharmaceutical ingredients (APIs), which is currently in an earlier stage of pre-clinical development.
